Key facts
- Sonire Therapeutics completed enrollment in its SUNRISE-I randomized controlled trial.
- The trial evaluates ultrasound-guided HIFU therapy for pancreatic cancer.
- The study is pivotal and based in Japan.
- This trial complements an ongoing U.S. clinical program.
Pancreatic cancer is an aggressive cancer with limited treatment options. Non-invasive therapies like High-Intensity Focused Ultrasound (HIFU) offer potential advantages, and clinical trials are crucial to establish their efficacy and safety.